Cardiff Oncology Secures $40 Million in Funding to Advance Promising Oncology Drug Development Programs

Cardiff Oncology, a pioneering clinical-stage biotechnology company based in San Diego, CA, has successfully raised $40 million to accelerate the clinical development of its promising therapies targeting various cancers. This significant funding effort will primarily support the advancement of onvansertib, Cardiff’s lead asset, a potent PLK1 inhibitor. Onvansertib is currently undergoing rigorous evaluation in combination with standard-of-care treatments against challenging conditions such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). Additionally, the funding will aid in investigator-initiated trials focusing on triple-negative breast cancer (TNBC) and small cell lung cancer (SCLC), all indications where urgent treatments are desperately needed. Cardiff's innovative approach taps into the potential of PLK1 inhibition to exploit tumor vulnerabilities, aiming to effectively combat treatment resistance and deliver enhanced clinical outcomes compared to current therapies. This influx of capital underscores the confidence investors have in Cardiff Oncology's vision and commitment to transforming cancer care through advanced biotechnology. As the company embarks on this crucial phase of its journey, stakeholders and patients alike can look forward to breakthroughs that could profoundly impact the treatment landscape for some of the most challenging cancers. For further information and updates on Cardiff Oncology’s transformative work, please visit their website at https://www.cardiffoncology.com.